Join Growin Stock Community!

British american tobacco plc(BTI.US AI Earnings Summary)

US StockConsumer Defensive
No presentation for BTI

BTI AI Earnings Summary (In-Depth)

Last updated: 2026-02-12 (US time)

2025 Q4

Key Highlights

  • Stock Price Reaction: Results were released at 7:00 a.m. London time on February 12, 2026, before the U.S. open; on that first trading day after earnings, the ADR closed at $60.61, up 0.46% from the February 11 close of $60.33.
  • Market Expectations: FY2025 revenue grew 2.1% YoY, adjusted operating profit grew 2.3% YoY, and adjusted diluted EPS grew 3.4% YoY; financial results reached the upper end of previous expectations.
  • Guidance Achievement: Successfully delivered on all FY2025 priorities, with financial results at the top end of the company's original constant-currency guidance range, demonstrating strong execution.
  • In a Nutshell: Despite strong progress in the smokeless product transformation and earnings reaching the upper end of expectations in FY2025, management estimates FY2026 performance will fall at the lower end of medium-to-long-term growth targets. The market viewed this cautiously, responding with a 1.83% decline on closing day.

Quarterly Highlights

  1. U.S. Business Returns to Growth: 2025 U.S. revenue grew 4.6% YoY and adjusted profit grew 5.9% YoY, marking the first full-year positive growth since 2022. The combustibles business contributed 1% to revenue growth and gained 30 basis points of value market share.

  2. Global Leadership in Modern Oral Products: Velo Plus achieved 300% growth in its first year of launch, capturing 80% of industry value growth in December. Global modern oral market share reached leadership positions in key markets, with Velo's scale in Europe being 6 times that of its nearest competitor.

  3. New Category Contribution Increases Significantly: New Category contribution grew 77% YoY to £442M, with gross profit increasing by over £200M. The category contribution has improved by a cumulative £1.4B since 2021, demonstrating economies of scale and investment discipline.

  4. Full-Year Performance Better Than Expected: Group revenue grew 2.1% YoY, adjusted operating profit grew 2.3% YoY, and adjusted diluted EPS grew 3.4% YoY, all reaching the upper end of full-year guidance, with visible acceleration in momentum during the second half.

  5. Cash Returns Continue to Strengthen: 2026 dividend increased 2% YoY; share buyback amount was raised by £200M to £1.3B. Adjusted net debt to EBITDA decreased to 2.55x, and the cumulative free cash flow target of over £50B by 2030 remains maintained.

  6. Productivity Program Accelerates: Cumulative cost savings of £1.2B realized since 2023. The Fit2Win program was revised upward to contribute £600M in annual savings by 2028, with a target of saving an additional £2B by 2030.

  7. U.S. Regulatory Environment Turns Positive: Vuse returned to revenue growth in the second half; state-level enforcement covers 50% of the legal market. The FDA initiated streamlined PMTA reviews for nicotine pouches, and an ITC preliminary ruling favored the exclusion of illicit products.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer